← Feed

$CTXR

4 theses
bullish 100%neutral 0%bearish 0%
Avg return (3m)
+11.9%
Win rate (3m)
75% (4 resolved)
1d3d1w1m3m6m1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

$CTXRr/pennystocksSuspicious Replies/Awardsbullish
u/genericasallfuck · 1966d agono track record yet

$CTXR – Citius will help save lives and lower healthcare costs while also making money – a win³. That's my prediction. Do the DD for yourself, of course.

Citius' Mino-Lok product addresses a real clinical need with limited competition and solid Phase 2 data, while management has significant personal investment in the company. The author expects strong upside from this pipeline as institutions adopt the stock and the company achieves commercial success.

At post $90.00live price unavailable
1d+2.5%
3d+2.5%
1w+9.4%
1m-46.4%
3m-43.6%
6m-53.9%
1y-75.5%
original post →
$CTXRr/pennystocksTechnical Analysisbullish
u/SlurpyBanana · 2059d agono track record yet
“Got in below $2”

3 month chart for $CTXR. Low PT $4, high $8. Glad to get in below $2

Technical analysis shows price targets between $4 and $8 on a 3-month chart. The author entered below $2, positioning for significant upside from current levels.

At post $46.25live price unavailable
1d+7.6%
3d+8.1%
1w+7.6%
1m-7.6%
3m+48.6%
6m+12.4%
1y-12.4%
original post →
$CTXRr/pennystocksBullishbullish
u/Twister699 · 2067d agono track record yet

CTXR Acute Respiratory Conditions help/cure worth billions

CTXR's stem-cell therapy for post-COVID acute respiratory conditions addresses a massive market of 76% of 117M+ hospitalized patients with lingering symptoms. The fast-tracked treatment combined with Mino-Lok launch will drive stock to all-time highs over the next year as a multi-billion dollar cash cow.

At post $48.00live price unavailable
1d-5.2%
3d-0.5%
1w-3.6%
1m-5.2%
3m+32.8%
6m+9.4%
1y-20.3%
original post →
$CTXRr/pennystocksDDbullish
u/SherstockHolmes · 2075d agono track record yet

Citius Pharmaceuticals ($CTXR) - The Next Billion Dollar Pharmaceutical Company?

Citius Pharmaceuticals is developing Mino-Lok, a novel treatment for central line infections with a >$1.5B market, addressing a massive unmet need affecting 472k infections annually. Phase 3 trials are progressing toward early completion expected by April, supported by leadership's $26.5M personal investment and strong efficacy data showing 100% catheter salvage rates versus 0% complication rates in Phase 2b testing.

At post $52.00live price unavailable
1d—
3d-7.7%
1w-13.9%
1m-11.1%
3m+9.6%
6m+5.3%
1y-26.0%
original post →

End of results.